Literature DB >> 17661045

[Risk-adapted multimodal laboratory cervical screening---Pap test of the future?].

R Bollmann1, A D Varnai, A Bankfalvi, M Bollmann.   

Abstract

The objective of screening for cervical cancer is to reduce mortality and incidence of the disease. To date there is extensive and strong evidence that this can be achieved by cytology-based screening programs, which continue to be the mainstay of cervical prevention worldwide despite their inherent methodological limitations. This article presents a review on the utility of conventional, ancillary and experimental methods for cervical screening both as single tests and test combinations, and describes possible future directions for enhanced screening accuracy using risk-adapted protocols.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661045     DOI: 10.1007/s00292-007-0923-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   0.973


  29 in total

1.  Epidemiological aspects of cancer screening in Germany.

Authors:  Nikolaus Becker
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-14       Impact factor: 4.553

2.  International incidence rates of invasive cervical cancer after introduction of cytological screening.

Authors:  L Gustafsson; J Pontén; M Zack; H O Adami
Journal:  Cancer Causes Control       Date:  1997-09       Impact factor: 2.506

3.  Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy.

Authors:  A Schneider; H Hoyer; B Lotz; S Leistritza; R Kühne-Heid; I Nindl; B Müller; J Haerting; M Dürst
Journal:  Int J Cancer       Date:  2000-11-20       Impact factor: 7.396

4.  Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples.

Authors:  Reinhard Bollmann; Gábor Méhes; Robert Torka; Norbert Speich; Christoph Schmitt; Magdolna Bollmann
Journal:  Cancer       Date:  2003-04-25       Impact factor: 6.860

5.  Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.

Authors:  M A Nobbenhuis; J M Walboomers; T J Helmerhorst; L Rozendaal; A J Remmink; E K Risse; H C van der Linden; F J Voorhorst; P Kenemans; C J Meijer
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

6.  Identification of progressive cervical epithelial cell abnormalities using DNA image cytometry.

Authors:  Hans Juergen Grote; Huy V Q Nguyen; Anand Gilbert Leick; Alfred Böcking
Journal:  Cancer       Date:  2004-12-25       Impact factor: 6.860

7.  Can we detect cervical human papillomavirus (HPV) infection by cytomorphology alone? Diagnostic value of non-classic cytological signs of HPV effect in minimally abnormal Pap tests.

Authors:  M Bollmann; A Bánkfalvi; A Trosic; N Speich; C Schmittt; R Bollmann
Journal:  Cytopathology       Date:  2005-02       Impact factor: 2.073

8.  International trends in incidence of cervical cancer: II. Squamous-cell carcinoma.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; J Borras; D M Parkin
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

Review 9.  Findings to date from the ASCUS-LSIL Triage Study (ALTS).

Authors:  Mark Schiffman; Diane Solomon
Journal:  Arch Pathol Lab Med       Date:  2003-08       Impact factor: 5.534

10.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

View more
  1 in total

1.  Performance of a polymer-based DNA chip platform in detection and genotyping of human papillomavirus in clinical samples.

Authors:  T Schenk; T Brandstetter; A Zur Hausen; J Alt-Mörbe; D Huzly; J Rühe
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.